- Home
- ZLAB vs OKLO Comparison
ZLAB vs OKLO Comparison
Compare ZLAB & OKLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- OKLO
- Stock Information
- Founded
- ZLAB 2013
- OKLO 2013
- Country
- ZLAB China
- OKLO United States
- Employees
- ZLAB N/A
- OKLO N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- OKLO
- Sector
- ZLAB Health Care
- OKLO
- Exchange
- ZLAB Nasdaq
- OKLO NYSE
- Market Cap
- ZLAB 3.6B
- OKLO 3.1B
- IPO Year
- ZLAB 2017
- OKLO N/A
- Fundamental
- Price
- ZLAB $29.76
- OKLO $52.04
- Analyst Decision
- ZLAB Buy
- OKLO Buy
- Analyst Count
- ZLAB 4
- OKLO 8
- Target Price
- ZLAB $47.37
- OKLO $52.67
- AVG Volume (30 Days)
- ZLAB 944.8K
- OKLO 24.0M
- Earning Date
- ZLAB 05-08-2025
- OKLO 05-13-2025
- Dividend Yield
- ZLAB N/A
- OKLO N/A
- EPS Growth
- ZLAB N/A
- OKLO N/A
- EPS
- ZLAB N/A
- OKLO N/A
- Revenue
- ZLAB $418,326,000.00
- OKLO N/A
- Revenue This Year
- ZLAB $44.07
- OKLO N/A
- Revenue Next Year
- ZLAB $49.13
- OKLO N/A
- P/E Ratio
- ZLAB N/A
- OKLO N/A
- Revenue Growth
- ZLAB 43.72
- OKLO N/A
- 52 Week Low
- ZLAB $16.01
- OKLO $5.35
- 52 Week High
- ZLAB $39.77
- OKLO $59.14
- Technical
- Relative Strength Index (RSI)
- ZLAB 44.77
- OKLO 75.44
- Support Level
- ZLAB $30.11
- OKLO $49.41
- Resistance Level
- ZLAB $31.34
- OKLO $57.57
- Average True Range (ATR)
- ZLAB 1.06
- OKLO 4.80
- MACD
- ZLAB -0.02
- OKLO 1.55
- Stochastic Oscillator
- ZLAB 36.04
- OKLO 80.53
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About OKLO OKLO INC
Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.